Can Dopamine Responsiveness Be Predicted in Parkinson’s Disease Without an Acute Administration Test?

Author:

Betrouni Nacim1,Moreau Caroline12,Rolland Anne-Sophie1,Carrière Nicolas123,Viard Romain13,Lopes Renaud13,Kuchcinski Gregory14,Eusebio Alexandre5,Thobois Stephane6,Hainque Elodie7,Hubsch Cecile8,Rascol Olivier9,Brefel Christine9,Drapier Sophie10,Giordana Caroline11,Durif Franck11,Maltête David12,Guehl Dominique13,Hopes Lucie14,Rouaud Tiphaine15,Jarraya Bechir16,Benatru Isabelle17,Tranchant Christine18,Tir Melissa19,Chupin Marie20,Bardinet Eric21,Defebvre Luc12,Corvol Jean-Christophe722,Devos David12,

Affiliation:

1. University Lille, INSERM, CHU Lille, U1172 – LilNCog – Lille Neuroscience & Cognition, LICEND, Lille, France

2. CHU Lille, Neurology and Movement Disorders Department, Reference Center for Parkinson’s Disease, Lille, France; NS-Park French Network

3. University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, France; NS-Park French Network

4. CHU Lille, Neuroradioloy Department, Lille, France

5. Aix Marseille Universitë, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, UMR CNRS 7289, Institut de Neuroscience de La Timone, Marseille, France; NS-Park French Network

6. Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Neurologie C, Bron, France

7. Dëpartement de Neurologie, Hôpital Pitië-Salpêtrière, AP-HP, Paris, France; NS-Park French Network

8. Fondation Ophtalmologique A de Rothschild, Unitë James Parkinson, Paris, France; NS-Park French Network

9. University of Toulouse 3, University Hospital of Toulouse, INSERM, Departments of Neuroscience and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France; NS-Park French Network

10. Service de Neurologie, CHU Pont Chaillou, 2 rue Henri le Guilloux, Rennes cedex, France; NS-Park French Network

11. Universitë Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France; NS-Park French Network

12. Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France; NS-Park French Network

13. Service d’Explorations Fonctionnelles du Système Nerveux, Institut des Maladies Neurodëgënëratives Cliniques, CHU de Bordeaux, Bordeaux, France; NS-Park French Network

14. Neurology Department, Nancy University Hospital, Nancy, France; NS-Park French Network

15. Clinique Neurologique, Hôpital Guillaume et Renë Laennec, Boulevard Jacques Monod, Nantes Cedex, France; NS-Park French Network

16. Movement Disorders Unit, Foch Hospital, Universitë Paris-Saclay (UVSQ), INSERM U992, NeuroSpin, CEA Paris-Saclay, Suresnes, France; NS-Park French Network

17. Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, Poitiers, France; NS-Park French Network

18. Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut de Gënëtique et de Biologie Molëculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Universitë de Strasbourg, Illkirch, France; Fëdëration de Mëdecine Translationnelle de Strasbourg (FMTS), Universitë de Strasbourg, Strasbourg, France; NS-Park French Network

19. Department of Neurosurgery, Amiens University Hospital, Amiens, France; Medical Imaging Unit, Amiens University Hospital, Amiens, France; BioFlowImage Research Group, Jules Verne University of Picardie, Amiens, France; NS-Park French Network

20. CATI, Institut du Cerveau et de le Moelle Epinière, ICM, INSERM U1127, CNRS UMR7225, Sorbonne Universitë, Paris, France

21. Institut du Cerveau et de le Moelle Epinière, ICM, INSERM U1127, CNRS UMR7225, Sorbonne Universitë, Paris, France

22. Facultë de Mëdecine de Sorbonne Universitë, UMR S 1127, INSERM U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle Epinière, Paris, France; NS-Park French Network

Abstract

Background: Dopamine responsiveness (dopa-sensitivity) is an important parameter in the management of patients with Parkinson’s disease (PD). For quantification of this parameter, patients undergo a challenge test with acute Levodopa administration after drug withdrawal, which may lead to patient discomfort and use of significant resources. Objective: Our objective was to develop a predictive model combining clinical scores and imaging. Methods: 350 patients, recruited by 13 specialist French centers and considered for deep brain stimulation, underwent an acute L-dopa challenge (dopa-sensitivity > 30%), full assessment, and MRI investigations, including T1w and R2* images. Data were randomly divided into a learning base from 10 centers and data from the remaining centers for testing. A machine selection approach was applied to choose the optimal variables and these were then used in regression modeling. Complexity of the modelling was incremental, while the first model considered only clinical variables, the subsequent included imaging features. The performances were evaluated by comparing the estimated values and actual values Results: Whatever the model, the variables age, sex, disease duration, and motor scores were selected as contributors. The first model used them and the coefficients of determination (R2) was 0.60 for the testing set and 0.69 in the learning set (p < 0.001). The models that added imaging features enhanced the performances: with T1w (R2 = 0.65 and 0.76, p < 0.001) and with R2* (R2 = 0.60 and 0.72, p < 0.001). Conclusion: These results suggest that modeling is potentially a simple way to estimate dopa-sensitivity, but requires confirmation in a larger population, including patients with dopa-sensitivity < 30%

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference37 articles.

1. Levodopa: 50 years of a revolutionary drug for Parkinson’s disease;Fahn;Mov Disord,2015

2. Levodopa response in early Parkinson’s disease;Hauser;Mov Disord,2009

3. Levodopa and the progression of Parkinson’s disease;Fahn;N Engl J Med,2004

4. Predicting Parkinson’s disease progression: Evaluation of ensemble methods in machine learning;Nilashi;J Healthc Eng,2022

5. Prediction of the Levodopa Challenge Test in Parkinson’s disease using data from a wrist-worn sensor;Khodakarami;Sensors (Basel),2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3